Object The Basic Score for Brain @entity3 (BSBM) proposed by Lorenzoni and colleagues is one of the best grading systems for predicting survival periods after stereotactic radiosurgery (SRS) for brain metastases. However, it includes no brain factors and cannot predict neurological outcomes, such as preservation of neurological function and prevention of @entity16 . Herein, the authors propose a modified BSBM, adding 4 brain factors to the original BSBM, enabling prediction of neurological outcomes, as well as of overall survival, in @entity1 undergoing SRS. Methods To serve as neurological prognostic scores (NPSs), the authors scored 4 significant brain factors for both preservation of neurological function (qualitative survival) and prevention of @entity16 (neurological survival) as 0 or 1 as described in the following: > 10 @entity1313 = 0 or  <= 10 = 1, total @entity5 volume > 15 cm(3) = 0 or  <= 15 cm(3) = 1, MRI findings of localized meningeal dissemination (yes = 0 or no = 1), and neurological symptoms (yes = 0 or no = 1). According to the sum of NPSs, @entity1 were classified into 2 subgroups: Subgroup A with a total @entity11989 of 3 or 4 and Subgroup B with an @entity11989 of 0, 1, or 2. The authors defined the modified BSBM according to the @entity11989 subgroup classification applied to the original BSBM groups. The validity of this modified BSBM in 2838 consecutive @entity1 with brain metastases treated with SRS was verified. Results @entity1 included 1868 with @entity2 (including 1604 with @entity1149 ), 355 of the gastrointestinal tract, 305 of the breast, 176 of the urogenital tract, and 134 with other @entity5 . Subgroup A had 2089 @entity1 and Subgroup B 749. Median overall survival times were 2.6 months in BSBM 0 (382 @entity1 ), 5.7 in BSBM 1 (1143), 11.4 in BSBM 2 (1011) and 21.7 in BSBM 3 (302), and pairwise differences between the BSBM groups were statistically significant (all p < 0.0001). One-year qualitative survival rates were 64.6% (modified BSBM 0A, 204 @entity1 ), 45.0% (0B, 178), 82.5% (1A, 825), 63.3% (1B, 318), 86.4% (2A, 792), 73.7% (2B, 219), 91.4% (3A, 268), and 73.5% (3B, 34). One-year neurological survival rates were 82.6% (0A), 52.4% (0B), 90.5% (1A), 78.1% (1B), 91.1% (2A), 83.2% (2B), 93.9% (3A), and 76.3% (3B), where A and B identify the subgroup. Statistically significant differences in both qualitative and neurological survivals between Subgroups A and B were detected in all BSBM groups. Conclusions The authors' new index, the modified BSBM, was found to be excellent for predicting neurological outcomes, independently of life expectancy, in SRS-treated @entity1 with brain metastases.

A new grading system focusing on neurological outcomes for brain metastases treated with stereotactic radiosurgery: the modified Basic Score for Brain XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity1313 :: ('MESH:D001932', 'Disease') :: ['brain tumors'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancers'] @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological death'] @entity2 :: ('MESH:D008175', 'Disease') :: ['cancer of the lung'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['non-small cell lung cancer'] @entity3 :: ('MESH:D009362', 'Disease') :: ['Metastases'] @entity11989 :: ('MESH:D009261', 'Disease') :: ['NPS']
@entity3 :: (MESH:D009362,Disease) :: ['Metastases']
